-
公开(公告)号：US20200022987A1
公开(公告)日：2020-01-23
申请号：US16454835
申请日：2019-06-27
Applicant: Epizyme, Inc. , Eisai R&D Management Co., Ltd.
Inventor： Heike KEILHACK , Sarah K. KNUTSON , Danielle Johnston BLACKWELL , Larisa REYDERMAN , Lone OTTESEN
IPC: A61K31/5377 , C07D213/65 , C07D405/12 , A61K31/4412 , A61K31/4545
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
-
公开(公告)号：US20200009152A1
公开(公告)日：2020-01-09
申请号：US16444579
申请日：2019-06-18
Applicant: Epizyme, Inc.
Inventor： Heike KEILHACK
IPC: A61K31/5377 , A61P37/00 , A61P35/00 , A61K31/453 , A61K31/45 , A61K45/06
Abstract: The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
-
公开(公告)号：US20190175604A1
公开(公告)日：2019-06-13
申请号：US16181747
申请日：2018-11-06
Applicant: Epizyme, Inc. , Eisai R&D Management Co., Ltd.
Inventor： Heike KEILHACK , Sarah K. KNUTSON , Danielle Johnston BLACKWELL , Larisa REYDERMAN , Lone OTTESEN
IPC: A61K31/5377 , C07D405/12 , A61K31/4545 , A61K31/4412 , C07D213/65
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
-
公开(公告)号：US20190083504A1
公开(公告)日：2019-03-21
申请号：US15766474
申请日：2016-10-05
Inventor： Heike KEILHACK , Nigel J. WATERS , Rajeev VIBHAKAR
IPC: A61K31/5377 , A61K9/00 , A61P35/00
Abstract: The disclosure provides a method of treating a medulloblastoma in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.
-
Patent Agency Ranking
公开(公告)号：US20190038633A1
公开(公告)日：2019-02-07
申请号：US16075855
申请日：2017-02-08
Applicant: Epizyme, Inc.
Inventor： Jesse SMITH , Heike KEILHACK , Scott RIBICH
IPC: A61K31/5377 , A61P35/00 , A61K31/4412 , A61K31/496 , A61K31/551 , A61K31/553 , A61K9/00
Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20180289717A1
公开(公告)日：2018-10-11
申请号：US15567838
申请日：2016-04-20
Applicant: Epizyme, Inc. , Health Research, Inc.
Inventor： Heike KEILHACK , Roberto PILI
IPC: A61K31/5377 , A61K31/496 , A61K31/404 , A61P35/00
Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20180280402A1
公开(公告)日：2018-10-04
申请号：US15809445
申请日：2017-11-10
Applicant: Epizyme, Inc.
Inventor： Heike KEILHACK , Sarah K. KNUTSON , Kevin W. KUNTZ
IPC: A61K31/5377 , C07K16/28 , A61K31/573 , A61K45/06 , A61K39/395 , A61K31/69 , A61K31/675 , A61K31/635 , A61K31/404 , A61K31/52 , A61K31/519 , A61K31/4965 , A61K31/496 , A61K31/4375 , A61K31/436 , A61K39/00
CPC classification number: A61K31/5377 , A61K31/404 , A61K31/436 , A61K31/4375 , A61K31/496 , A61K31/4965 , A61K31/519 , A61K31/52 , A61K31/573 , A61K31/635 , A61K31/675 , A61K31/69 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2887 , A61K2300/00
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20170360797A1
公开(公告)日：2017-12-21
申请号：US15527375
申请日：2015-11-17
Applicant: Epizyme, Inc. , Eisai R&D Management Co., Ltd.
Inventor： Heike KEILHACK , Brett TRUITT , Yuta SUZUKI , Tsukasa MURASE , Futoshi SHIKATA
IPC: A61K31/5377 , A61K9/20 , A61K9/00 , A61K9/28
Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
-
公开(公告)号：US20170305890A1
公开(公告)日：2017-10-26
申请号：US15598262
申请日：2017-05-17
Applicant: Epizyme, Inc.
Inventor： Sarah K. KNUTSON , Natalie WARHOLIC , Heike KEILHACK
IPC: C07D405/14 , C07D405/12 , C07D211/86 , A61K31/5377 , A61K31/4545 , C12Q1/68 , A61K31/4412
CPC classification number: C07D405/14 , A61K31/4412 , A61K31/4545 , A61K31/5377 , C07D211/86 , C07D405/12 , C12Q1/6886
Abstract: The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
-
-
-
-
-
-
-
-
Search Results
49
records
(took 0.04 seconds)
